

## Special Issue

# Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition

### Message from the Guest Editors

It is my pleasure to invite you to contribute to the Special Issue entitled “Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition”. This is one new edition; we published 11 papers in the first edition. For more details, please

visit: [https://www.mdpi.com/journal/jcm/special\\_issues/627ZWHN1UZ](https://www.mdpi.com/journal/jcm/special_issues/627ZWHN1UZ)

Despite the advances in the diagnosis and treatment of pulmonary embolism and thrombosis that have been made over recent years, challenges remain in the management of PE and thrombosis. These include prevention, treatment, and management for patients with pulmonary embolism and thrombosis; continued research and innovation in this field will further enhance our understanding and management of these conditions, ultimately leading to better outcomes for patients. This Special Issue aims to report the latest research on pulmonary embolism and thrombosis. We would like to cordially invite you to submit your manuscripts for review and publication in the *Journal of Clinical Medicine* to improve clinical outcomes as well as ensure optimal short- and long-term management.

Prof. Dr. Elena Campello

Please click [here](#) to find more information.

---

### Guest Editors

Dr. Andrea Boccattonda

1. Internal Medicine, Bentivoglio Hospital, AUSL Bologna, 40010 Bologna, Italy
2. Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy

Prof. Dr. Elena Campello

Internal Medicine, Hemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED), Padova University Hospital, 35121 Padova, Italy

---

### Deadline for manuscript submissions

25 October 2026



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/251662](https://www.mdpi.com/si/251662)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://www.mdpi.com/journal/)

[jcm](https://www.mdpi.com/journal/jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).